Dr Filip Janku, MD, PhD is an Associate Professor in the Department of Investigational Cancer Therapeutics (Phase I Program) at MD Anderson Cancer Center.

Dr Janku obtained his MD and PhD at the Charles University Prague. He joined the Department of Investigational Cancer Therapeutics in the 2011 after completion of the drug development fellowship at the same institution.

Dr Janku is a principal investigator for numerous phase I trials, most of which involve novel, targeted agents, many of those being novel first-in-human studies; he received multiple awards for his research efforts, including the Khalifa award, Sidney Kimmel Scholar award, several ASCO Merit Awards as well as an American Association for Cancer Research Scholar-in-Training Award.

Dr Janku has published over 170 articles in peer-reviewed journals and his academic research interests focus on proof-of-concept clinical trials that possess a pivotal correlative component especially those involving liquid biopsies, molecular profiling of cell-free DNA, the PI3K/AKT/mTOR, MAPK, IDH pathways and therapeutic use of oncolytic bacteria.